NSE · Healthcare · Drug Manufacturers - Specialty & Generic
with an average price target of ₹53.00.
| Holder | Stake |
|---|---|
| Quant Mutual Fund - Quant Business Cycle Fund | 9.90% |
| Saumik Ketankumar Doshi | 1.20% |
| One Up Financial Consultants Pvt Ltd | 1.02% |
| Document | Date |
|---|---|
| Annual report FY2026 BROOKS LABORATORIES LIMITED — ANNUAL REPORT 2025-26 SUMMARY HEADLINE NUMBERS • Revenue from operations: Rs. 8,573.84 lakhs (FY 2025-26) vs Rs. 8,255 | 2026-08-21 |
| Quarterly results · Q1 FY27 BROOKS LABORATORIES LIMITED – Q1 FY2027 FINANCIAL SUMMARY HEADLINE NUMBERS • Standalone Revenue from Operations (Q1 FY27): Rs. 2,296.08 lakhs vs Rs. | 2026-08-13 |
| Annual report FY2026 BROOKS LABORATORIES LIMITED – ANNUAL REPORT 2025-26 SUMMARY HEADLINE NUMBERS • Revenue from operations: Rs. 8,573.84 lakhs (FY 2025-26) vs Rs. 8,255 | 2026-08-12 |
| Quarterly results · Q4 FY26 BROOKS LABORATORIES LIMITED – FINANCIAL SUMMARY Board Meeting Outcome, 29th May 2026 --- HEADLINE NUMBERS • FY 2025-26 Revenue from Operations (Sta | 2026-05-29 |
| Quarterly results · Q3 FY26 BROOKS LABORATORIES LIMITED – FINANCIAL RESULTS SUMMARY Quarter & Nine Months Ended 31 December 2025 --- HEADLINE NUMBERS STANDALONE (Company Only) | 2026-02-06 |
| Quarterly results · Q2 FY26 BROOKS LABORATORIES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Quarter ended Sept 30, 2025 (Standalone): Revenue Rs 2,345.07 Lakhs | Net Profit | 2025-11-14 |
| Annual report FY2025 BROOKS LABORATORIES LIMITED - ANNUAL REPORT 2024-25 SUMMARY --- HEADLINE NUMBERS • Total Revenue from Operations: Rs. 8,255.68 lakhs (FY 2024-25) v | 2025-09-04 |
| Quarterly results · Q1 FY26 BROOKS LABORATORIES LIMITED – Q1 FY2025-26 FINANCIAL SUMMARY HEADLINE NUMBERS • Standalone Revenue from Operations (Q1): Rs. 2,551.19 Lakhs (vs. Rs. | 2025-08-13 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Brooks Laboratories Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.